title: Thrombolysis of venous and arterial thrombosis by catheter-directed low-dose infusion of tissue plasminogen activator in children.
abstract: Thrombolytic therapy is a well-defined treatment option for arterial and venous thrombosis in adults. In contrast, uniform recommendations regarding the indication, route of administration, and dosing of thrombolytic therapy in children are not available. The authors report the successful resolution of bilateral pulmonary embolism and popliteal artery thrombosis in an 11-year-old girl and 13-year-old girl, respectively, by catheter-directed thrombolysis with low-dose recombinant tissue plasminogen activator. Catheter-directed low-dose thrombolysis is an efficient treatment option for severe venous and arterial thrombosis in children.
authors.affiliation: Division of Intensive Care, University Children's Hospital, Zurich, Switzerland. vincenzo.cannizzaro@kispi.unizh.ch
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Cannizzaro
authors.forename: Felix
authors.initials: F
authors.lastname: Berger
authors.forename: Oliver
authors.initials: O
authors.lastname: Kretschmar
authors.forename: Rotraud
authors.initials: R
authors.lastname: Saurenmann
authors.forename: Walter
authors.initials: W
authors.lastname: Knirsch
authors.forename: Manuela
authors.initials: M
authors.lastname: Albisetti
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001182:Arthroscopy; D002648:Child; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006406:Hematoma / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007269:Injections, Intra-Arterial; D007718:Knee Injuries / Q000601:surgery; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications; D010644:Phenprocoumon / Q000008:administration & dosage / Q000627:therapeutic use; D011150:Popliteal Artery; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D011374:Progesterone / Q000627:therapeutic use; D011651:Pulmonary Artery; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D025064:Sex Chromosome Disorders / Q000150:complications / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000295:instrumentation / Q000379:methods*; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014314:Trisomy
chemical_list: D000925:Anticoagulants; D004967:Estrogens; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D011374:Progesterone; D006493:Heparin; D010959:Tissue Plasminogen Activator; D010644:Phenprocoumon